Search website

If you cannot find, what you are looking for, try searching for it below or visit our FAQ-page.



Tillotts Pharma AG announces launch of Asacol® 800mg Tablets in the People’s Republic of China

RHEINFELDEN, Switzerland, 28.07.2021 – Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, is pleased to announce the recent launch of Asacol®800 mg tablets (mesalazine) as first-line treatment for mild to moderate ulcerative colitis (UC) in the People’s Republic of China (“China”).

After announcing the successful partnership of Tillotts and Menarini in October 2019, and regulatory approval of Asacol®800 mg in April 2020, the launch of the tablets represents a major milestone for both companies.

Bringing Asacol® to the market began several years ago with the conduct of two Phase III studies in the local population. The introduction of this high strength mesalazine tablet formulation to the Chinese market is expected to optimise the therapeutic options of patients living with UC in China.

Mattias Norrman, Chief Operations Officer at Tillotts, said:

“We are very excited that we have now launched Asacol® in China and made it available to Chinese patients. This has been achieved through the close partnership between Tillotts and Menarini and the efforts and continued dedication of the teams involved. Providing the highest strength mesalazine tablet in the Chinese market may help improve patient adherence to chronic ulcerative colitis treatment. It is always a great satisfaction to ensure that UC patients around the world receive new first-line treatment opportunities.”

Mattias Norrman added:

“The commercial launch of Asacol® tablets will bring new treatment options in tablet formulation to clinicians. There is a substantial need for new treatment options in UC. According to statistics from the Chinese Center for Disease Control and Prevention, it is estimated that by 2025, the number of patients in China with IBD; a type of chronic non-specific intestinal inflammation, including ulcerative colitis and Crohn’s disease, will reach 1.5 million1.”


1Kaplan, Gilaad. (2015). The global burden of IBD: From 2015 to 2025. Nature reviews. Gastroenterology & hepatology. 12. 10.1038/nrgastro.2015.150.


For more information, please contact:

Tillotts Pharma AG
Susi Teichmann
Senior Manager Corporate Communications
Phone: +41 61 935 2759

About Tillotts

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma
company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the
development, acquisition and commercialisation of innovative pharmaceutical products for the
digestive system. Tillotts successfully markets its own products for the treatment of IBD and
Clostridoides difficile infection (CDI) as well as in-licensed products in around 65 countries
through its affiliates within Europe and a network of gastroenterology-focused partners
throughout the world.

All trademarks used or mentioned here are protected by law. © Copyright Tillotts Pharma AG. All rights reserved.

For more information, please visit

About Zeria

Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit


Download high-resolution photos here